Kinase Inhibitor for Cancer Therapy

Download Url(s)
https://mdpi.com/books/pdfview/book/9349Contributor(s)
Musumeci, Francesca (editor)
Language
EnglishAbstract
Cancer is one of the leading causes of death worldwide, yet considerable efforts are still required to make this pathology curable. Despite the limits of available approaches, kinase inhibitors have marked a turning point in the treatment of different types of tumors. This class of compounds is the first oral targeted therapy approved for neoplasia, and about 30 compounds have entered the market in the last five years. Kinase inhibitors include small molecules and monoclonal antibodies and are endowed with fewer side effects than classical antitumor agents. The potential for application of this class of drugs is substantial, and this Special Issue focuses on the discovery and development of kinase inhibitors in terms of in silico studies, synthesis and identification of new compounds, drug delivery, formulation studies, and biological and pharmacokinetic evaluation.
Keywords
JAK; synthesis; kinase inhibitory activity; pharmacological uses; binding mode/interactions; choline kinase; lipid metabolism; cisplatin; lung tumors; combinatorial chemotherapy; glioblastoma; Src; pyrazolo [3,4-d]pyrimidine scaffold; EGFR; multiple myeloma; tyrosine kinase; treatment; ibrutinib; gastric cancer; kinase inhibitor; ALK; targeted therapy; JNK3; fragment; saturation transfer difference NMR; X-ray crystallography; breast cancer; nanomedicine; PI3K?; poloxamers; polymeric nanoparticles; TPGS; zanubrutinib; anthracycline; drug resistance; aldo-keto reductase 1C3; ABC drug efflux transporter; Hsp90 inhibitor; co-chaperone; heterocycle molecules; anticancer agents; heat shock proteins; ER stress; PERK; UPR; kinase; inhibitor; cancer; diabetes; small molecule; structure–activity-relationship (SAR); MCL; ROR1; small molecules; apoptosis; AKT1; kinase inhibitors; acute myeloid leukemia; rare disease; molecular modeling; molecular docking; similarity search; MD simulation; computer-aided drug discovery; cutaneous T-cell lymphoma; TWIST1; erufosine; curcumin; synergy; nanotechnology; 3D tissue culture; 3D tumor model; tumor spheroids; drug screening; preclinical study; tyrosine kinase inhibitors; innate immunity; thyroid cancer; tumor-associated macrophages; cytokines; c-Src/Abl dual inhibitors; pyrazolo[3,4-d]pyrimidines; ADME; antiproliferative activity; childhood cancer; kinases; chemical inhibitors; clinical trials; dasatinib; CML; HIV-1; CMV; HIV functional cure; memory-like NK cells; ?? T cells; anti-aging; senolytic; NSCLC; KAN0441571C; erlotinib; TTP; rigosertib; ON-01910.Na; cancer therapy; kinase allosteric inhibition; Plk1; Ras; JNK; PI3K/Akt; microtubule-destabilizing agents; stress-signaling pathways; aptamer; MNK1; therapeutic target; non-small cell lung cancer; antitumor; 4,5,6,7-tetrabromo-N,N-dimethyl-1H-benzimidazol-2-amine (DMAT) derivatives; protein kinase CK2; protein kinase PIM-1; dual protein kinase inhibitors; antitumor activity; autophagy; hepatocellular carcinoma; EGFR/PI3K/AKT/mTOR signaling; animal models; n/aWebshop link
https://mdpi.com/books/pdfview ...ISBN
9783725812905, 9783725812899Publisher website
www.mdpi.com/booksPublication date and place
2024Classification
Mathematics and Science
Biology, life sciences
Molecular biology